UGT2B17 is also prognostic in chronic lymphocytic leukaemia (CLL), where high expression is associated with shorter treatment-free and overall survival primarily through its intracellular inactivation of anti-leukaemic drugs such as fludarabine [39]. Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.